Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from NeOnc Technologies Holdings, Inc. ( (NTHI) ).
On July 28, 2025, NeOnc Technologies Holdings, Inc. entered into a Subscription Agreement with Quazar for a $400,000 investment in its subsidiary, NuroMENA, reducing NeOnc’s stake to 80%. The agreement includes a $50 million investment plan, significantly diluting NeOnc’s equity in NuroMENA to 38% and marking a strategic partnership for expansion in the MENA region. Additionally, on July 30, 2025, NeOnc announced the acquisition of an AI, 3D, and Quantum Modeling IP Portfolio and the appointment of Dr. Ishwar K. Puri to its Board, further enhancing its technological capabilities.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing and commercializing therapeutics for the central nervous system, particularly targeting the blood-brain barrier. The company’s NEO™ drug development platform has produced novel drug candidates like NEO100™ and NEO212™, which are in Phase II clinical trials and have shown promise in treating malignant gliomas.
Average Trading Volume: 223,262
For a thorough assessment of NTHI stock, go to TipRanks’ Stock Analysis page.